Ze-Fei Jiang

472 total citations
6 papers, 115 citations indexed

About

Ze-Fei Jiang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Ze-Fei Jiang has authored 6 papers receiving a total of 115 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Genetics. Recurrent topics in Ze-Fei Jiang's work include HER2/EGFR in Cancer Research (3 papers), Cancer Treatment and Pharmacology (3 papers) and Breast Cancer Treatment Studies (2 papers). Ze-Fei Jiang is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Cancer Treatment and Pharmacology (3 papers) and Breast Cancer Treatment Studies (2 papers). Ze-Fei Jiang collaborates with scholars based in China, United States and Netherlands. Ze-Fei Jiang's co-authors include Li Zhou, Jianming Xu, Daniel T. T. Chua, Dong-Geng Liu, Winnie Yeo, Anne-Marie Martin, B. Newstat, Li Wang, Zhi-Min Shao and Huaqing Wang and has published in prestigious journals such as Breast Cancer Research and Treatment, Anti-Cancer Drugs and Cancer Management and Research.

In The Last Decade

Ze-Fei Jiang

6 papers receiving 110 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ze-Fei Jiang China	4	82	35	29	22	22	6	115
Candice Schwartz United States	4	104 1.3×	20 0.6×	82 2.8×	16 0.7×	16 0.7×	6	177
Eugenia Ortega Spain	6	44 0.5×	25 0.7×	42 1.4×	7 0.3×	36 1.6×	9	114
David Soong United States	6	30 0.4×	21 0.6×	42 1.4×	13 0.6×	12 0.5×	9	115
Amy Garrett United States	5	37 0.5×	35 1.0×	26 0.9×	6 0.3×	34 1.5×	6	94
Daniel Flora United States	4	70 0.9×	20 0.6×	8 0.3×	35 1.6×	16 0.7×	8	109
Fenja Seither Germany	6	102 1.2×	25 0.7×	25 0.9×	17 0.8×	65 3.0×	13	116
Shannon A. Slater United States	4	48 0.6×	19 0.5×	57 2.0×	27 1.2×	44 2.0×	10	112
F Marmé Germany	4	40 0.5×	17 0.5×	20 0.7×	16 0.7×	45 2.0×	6	75
Katarína Petráková Czechia	7	52 0.6×	40 1.1×	39 1.3×	37 1.7×	43 2.0×	23	113
Marc Cucurull Spain	6	79 1.0×	37 1.1×	31 1.1×	4 0.2×	12 0.5×	17	110

Countries citing papers authored by Ze-Fei Jiang

Since Specialization

Citations

This map shows the geographic impact of Ze-Fei Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ze-Fei Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ze-Fei Jiang more than expected).

Fields of papers citing papers by Ze-Fei Jiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ze-Fei Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ze-Fei Jiang. The network helps show where Ze-Fei Jiang may publish in the future.

Co-authorship network of co-authors of Ze-Fei Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Ze-Fei Jiang. A scholar is included among the top collaborators of Ze-Fei Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ze-Fei Jiang. Ze-Fei Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Liu, Guang‐Yu, Yan Xia, Da Pang, et al.. (2018). Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial. Cancer Management and Research. Volume 11. 299–307. 11 indexed citations

2.

Chen, Qiang, Huaqing Wang, Ze-Fei Jiang, et al.. (2013). Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens. Anti-Cancer Drugs. 24(6). 641–647. 20 indexed citations

3.

Jiang, Ze-Fei, Daniel T. T. Chua, Zhi-Min Shao, et al.. (2011). Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chinese Journal of Cancer. 30(5). 327–335. 36 indexed citations

4.

Jiang, Ze-Fei, et al.. (2010). [Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].. PubMed. 32(2). 158–60. 1 indexed citations

5.

Xu, Jian-Ming, et al.. (2001). Neoadjuvant Chemotherapy in Inoperable, Locally Advanced, and Inflammatory Breast Carcinoma. American Journal of Clinical Oncology. 24(3). 259–263. 3 indexed citations

6.

Xu, Jianming, et al.. (1999). Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Research and Treatment. 53(1). 77–85. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact